Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy

Wholebody Clearance Of Three 89Zr Labeled Antibodies:Differences between PET based and Whole Body Probe Based Clearance

Volkan Beylergil, Neeta Pandit-Taskar, Steven Larson, Michael Morris, Daniel C. Danila, Neil Bander, Bernard Fine, Jorge Carrasquillo, Wolfgang Weber and Joseph O'Donoghue
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1275;
Volkan Beylergil
1Radiology, MSKCC, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neeta Pandit-Taskar
1Radiology, MSKCC, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Larson
1Radiology, MSKCC, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Morris
3Medicine, MSKCC, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel C. Danila
3Medicine, MSKCC, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil Bander
2Urology, Weill Cornell Medical College, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Fine
4Genentech, San Franscisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Carrasquillo
1Radiology, MSKCC, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Weber
1Radiology, MSKCC, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph O'Donoghue
1Radiology, MSKCC, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

1275

Objectives For dosimetry,it is important to obtain whole body(WB) clearance data for the radiolabeled antibody that is being tested.We have been using both WB probe based and PET based clearance data.The aim of this study was to compare WB clearance data for 3 novel radiolabeled antibodies using probe based vs PET based measurements.

Methods We compared 10 patients injected with 89Zr-DFO-trastuzumab,10 with 89Zr-DFO-huJ591, and 6 with 89Zr-DFO-MSTP2109A(~5mCi). WB clearance was calculated based on background subtracted geometric mean counts from NaI(Tl) probe.PET based clearance was calculated by integrating total activity in all serial PET images.Probe measurements were made pre and post-void and on 3 additional days over an 8 day period.Data were fit to a single exponential and T1/2 effective was obtained.Probe measurements were compared to PET measurements using Bland-Altman analysis.

Results The coefficient of variation for the effective half-live (Teff) as measured by PET and WB probe was less than 10% for all antibodies. PET and WB probe based estimates of Teff were not significantly different for 89Zr-DFO-trastuzumab and 89Zr-DFO-MSTP2109A (p=0.25 and p=0.17), but were 7% higher for PET based measurements for 89Zr-DFO-huJ591 (p<0.002). This was probably due to concentration of activity in the liver over time.

Conclusions Estimates of WB clearance for 89Zr-antibodies based on either probe or PET images generally show only small differences.Systematic differences may occur if activity is over time concentrated in the field of view of the PET camera as observed in the present study for 89Zr-DFO-huJ591.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 56, Issue supplement 3
May 1, 2015
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Wholebody Clearance Of Three 89Zr Labeled Antibodies:Differences between PET based and Whole Body Probe Based Clearance
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Wholebody Clearance Of Three 89Zr Labeled Antibodies:Differences between PET based and Whole Body Probe Based Clearance
Volkan Beylergil, Neeta Pandit-Taskar, Steven Larson, Michael Morris, Daniel C. Danila, Neil Bander, Bernard Fine, Jorge Carrasquillo, Wolfgang Weber, Joseph O'Donoghue
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1275;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Wholebody Clearance Of Three 89Zr Labeled Antibodies:Differences between PET based and Whole Body Probe Based Clearance
Volkan Beylergil, Neeta Pandit-Taskar, Steven Larson, Michael Morris, Daniel C. Danila, Neil Bander, Bernard Fine, Jorge Carrasquillo, Wolfgang Weber, Joseph O'Donoghue
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1275;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy

  • Quantitative analysis of blood-borne 18F-FMISO metabolites in cancer patients by HPLC using an integrated high-sensitivity coincidence detector
  • Lesion detection and workflow optimization in whole body diffusion MR imaging using trimodality PET/CT+MR in the oncology setting.
  • What is the impact of 18F-FDG PET/CT in the management of iodine positive metastatic differentiated thyroid cancer.
Show more Oncology: Basic, Translational & Therapy

MTA I: Technical Advances & Quantification Posters

  • Quantitative analysis of blood-borne 18F-FMISO metabolites in cancer patients by HPLC using an integrated high-sensitivity coincidence detector
  • Successful PET Imaging of Pancreatic Tumors in Mice, Achieved by Reverse Contrast CT
  • Investigation of volume-of-interest (VOI) definition methods for estimating organ activity concentrations in quantitative SPECT (QSPECT)
Show more MTA I: Technical Advances & Quantification Posters

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire